- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Snapshot for Theravance Inc (THRX)
| Open: | 37.3700 | Day's Range: | 36.1000 - 37.9500 | Volume: | 1,381,409 |
|---|---|---|---|---|---|
| Previous Close: | 37.5200 | 52wk Range: | 17.0600 - 42.4100 | 1-Yr Rtn: | +69.38% |
Key Statistics for THRX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.5100 |
| Est. EPS (USD) (12/2013) | -1.3680 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 3,702.86 |
| Shares Outstanding (M) | 99.45 |
| 30 Day Average Volume | 2,215,382 |
| Price/Book (mrq) | 39.4076 |
| Price/Sale (ttm) | 343.9870 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/31/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for THRX
Company Profile & Key Executives for THRX
Theravance Inc., is a biopharmaceutical company. The Company develops small molecule medicines for respiratory disease, bacterial infections, and gastrointestinal disorders.
| Rick E WinninghamChairman/CEO | Michael W AguiarSenior VP/CFO |
| Leonard M BlumSenior Vice President | Bradford J ShaferSenior VP/Secy/Gen Counsel |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
THRX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page